Conference
Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma
Authors
Trudel S; McCurdy A; Sutherland H; Louzada M; Venner C; White D; Mian H; Kotb R; Othman I; Camacho F
Volume
21
Pagination
pp. S162-S162
Publisher
CIG MEDIA GROUP, LP
Publication Date
October 2021
Conference proceedings
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
ISSN
2152-2650